HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM)…
Browsing: BioTech
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd.…
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.…
Everest Medicines (HKG: 1952) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and…
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global…
SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce…
ASGH and Medical Fair open concurrently, showcasing cutting-edge AI, Robotics and MedTech The fifth International Healthcare Week (IHW), organised by the…
Holista Colltech Limited (ASX: HCT) (Holista or the Company) is pleased to announce that it has entered into a binding…
HONG KONG, Apr 28, 2026 – (ACN Newswire) – Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout…
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that, the Group through its wholly-owned subsidiary…
China Medical System Holdings Limited (the Group or CMS) is pleased to announce that the New Drug Application (NDA) in…
HONG KONG, Apr 22, 2026 – (ACN Newswire) – Hengrui Pharma reported steady growth in the first quarter of 2026. In…
– Demonstrating a Favorable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy Apr 20, Everest Medicines Limited announced that the first-in-human…
Avantor, Inc., a leading life science tools company and global provider of mission-critical products and services to the life sciences…
Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in…
Across the landscape of global biotech companies, the appointment of a senior executive often serves as a “barometer”—offering insights into…
China’s 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy…
– Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million,…
– Innovation and R&D Advance Steadily, RMB 31.83 Billion in Revenue Recorded – Underlying Profit Attributable to Owners of the…
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its…